ACE Technology Guidances communicate recommendations from the MOH Drug Advisory Committee or the MOH Medical Technology Advisory Committee on the funding status and appropriate use of drugs, vaccines or medical technologies that have been evaluated by ACE. The guidances also include the Committee’s rationale for the funding recommendations, and key clinical and economic evidence which informed their deliberations. Plain English Summaries (PES) to explain ACE Technology Guidances are available for patients and the public.

Published on 01 Apr 2022
Last Updated on 01 Apr 2022
A- A+
Guidance Recommendations

The Ministry of Health's Drug Advisory Committee has not recommended listing insulin glargine 300 units/ml on the Standard Drug List (SDL) for treating type 1 and 2 diabetes mellitus in view of unfavourable cost-effectiveness compared with insulin glargine 100 units/ml at the price proposed by the manufacturer, and low clinical need.

High-strength insulin glargine for treating type 1 and 2 diabetes mellitus (1 Apr 2022) High-strength insulin glargine for treating diabetes mellitus PES (1 Apr 2022)